Key result
High LASP-1 expression was independently associated with worse overall survival (HR 1.69) and recurrence-free survival (HR 1.67) in patients with clear cell renal cell cancer.
Why the study?
Is LASP-1 overexpression associated with poor prognosis in patients with clear cell renal cell cancer?
Observational (n=216)
No
Is LASP-1 overexpression associated with poor prognosis in patients with clear cell renal cell cancer?
LASP-1 overexpression is associated with aggressive tumor phenotypes and serves as an independent predictor of poor overall and recurrence-free survival in clear cell renal cell carcinoma.
Answers are grounded in this paper and cite their sources.
Supports LASP-1 as a prognostic marker in clear cell RCC; leaves open prospective validation before clinical use.
BACKGROUND: LIM and SH3 protein 1 (LASP-1) is a specific focal adhesion protein that is known to be involved in numerous biological and pathological processes. LASP-1 overexpression has been described in several types of cancers, but its expression and role in clear cell renal cell cancer (ccRCC) remains unknown. METHODS: Using immunohistochemistry, we analyzed LASP-1 protein expression in 216 clinicopathologically characterized ccRCC cases. We also examined LASP-1 expression in 20 paired ccRCC tissues and in 2 cell lines by real-time PCR and Western blot. Using RNA interference, we investigated the effects of LASP-1 depletion on tumor cell behavior in vitro. Statistical analyses were used to determine the associations between LASP-1 levels, tumor features and patient outcomes. RESULTS: LASP-1 overexpression was observed in ccRCC tissues (P<0.0001) compared to adjuvant nontumorous tissues, and its expression levels were closely correlated with overall survival and recurrence-free survival (P = 0.044 and 0.006, respectively) in patients with ccRCC. RNA interference-mediated silencing of the LASP-1 gene in 786-0 ccRCC cells significantly inhibited cell migration. CONCLUSIONS: The results of the present study indicate that LASP-1 may serve as a prognostic biomarker for ccRCC patients and may be a promising target for the treatment of ccRCC.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2014) conducted an observational in Clear cell renal cell cancer (n=216). LASP-1 overexpression vs. Low LASP-1 expression was evaluated on Overall survival (HR 1.69, 95% CI 1.01-2.81, p=0.044). High LASP-1 expression was independently associated with worse overall survival (HR 1.69) and recurrence-free survival (HR 1.67) in patients with clear cell renal cell cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: